DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/5g8pb3/investigation) has announced the addition of the "Investigation Report on China's Desloratadine Market, 2010-2019" report to their offering.
Histamine, a substance which can lead to inflammation and anaphylaxis, is one of the important chemical mediators of immediate anaphylaxis (the most common type I allergy in clinic). The incidence of allergies have always been high and show an increasing trend. According to the American Academy of Allergy, Asthma and Immunology, allergies have become the s
ixth chronic disease in the US with 20%-40% of the total population suffering from it. According to the statistics, the number of cases of allergic rhinitis in China exceeds 100 million and the incidence of allergic disease has reached about 30%.
For a long time, anti-histamine has been widely used for the desensitization treatment of allergic diseases especially allergic rhinitis and urticaria. Among all the patients with dermatosis in hospitals, those suffering from allergic dermatosis account for 30%. And 70% of them need anti-histamine, one representative of which is desloratadine. Developed by Sepracor and Schering-Plough, desloratadine first entered the British market in February 2201 and has now become a top-selling drug in the world.
Local enterprises in China started developing the generic drugs of desloratadine early. In 2002, Hainan Poly Pharm Co., Ltd, Shenzhen Haibin Pharmaceutical Co., Ltd and Salubris were all approved by CFDA to produce desloratadine's Active Pharmaceutical Ingredients (APIs) and tablets. Desloratadine develops fast after entering China with annual sales value rising from less than CNY 12 million in 2005 to CNY 185 million in 2014 and CAGR reaching up to 36% during the period of 2005-2014. Desloratadine enjoys a vast demand in China. Hainan Poly Pharm Co., Ltd, Hairui Pharmaceutical, Nanjing Hicin Pharmaceutical Co., Ltd, Shenzhen Haibin Pharmaceutical Co., Ltd and Salubris all take up certain shares in the market, among which Hairui Pharmaceutical has the largest market share of over 55% in 2014 for sales value while Hainan Poly Pharm Co., Ltd has the largest market share of 32.3% for sales volume.
Key Topics Covered:
1 Related Concepts of Desloratadine
2 Market Profile of Desloratadine in China
3 Survey on Sales Status of Desloratadine in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Desloratadine in China, 2010-2014
5 Survey on Dosage Forms of Desloratadine in China, 2010-2014
6 Reference Price of Desloratadine in Chinese Hospitals in 2014
7 Major Manufacturers of Desloratadine in Chinese Market, 2010-2014
8 Market Outlook of Desloratadine in China, 2015-2019
- Hairui Pharmaceutical
- Nanjing Hicin Pharmaceutical Co., Ltd
- Shenzhen Haibin Pharmaceutical Co., Ltd
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Hainan Poly Pharm Co., Ltd
For more information visit http://www.researchandmarkets.com/research/5g8pb3/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets